Survival analysis in adult Burkitt Lymphoma in Colombia according to HIV status

Introduction: Burkitt lymphoma is a highly aggressive Non-Hodgkin Lymphoma, is considered a rare tumor, accounts for only 1-2 % of adult lymphomas in North America. The two-year Overall survival rates was reported between 67 % and 84 %. Statistics from developing countries comes mainly from children studies in Africa where Burkitt Lymphoma is endemic. In Latin American countries, information about survival in adult population is scarce with limited number of patients and poor survival outcomes mainly in HIV associated Burkitt Lymphoma. The aim of this study is to evaluate survival in adults' patients with BL, and HIV status in a Colombian cohort. Materials and methods: A retrospective cohort study was conducted to determine the demographic characteristics, treatment, and survival of adult Burkitt Lymphoma patients in Colombia. The study included adult patients diagnosed with Burkitt Lymphoma between 2004 and 2023, and calculate Overall survival and progression free survival of the population, and according to HIV status Results: 83 patients were included for analysis with 49 (59 %) patients with a sporadic variant and 34 (41 %) with an immunodeficiency-associated variant. The median age at diagnosis was 40 years, IQR (30 - 52), The 36months OS was 49.9 % (95 % CI; 39.6 - 62.9 %)), and 36-months PFS was 51.5 % (95 % CI,41.5 - 64.5). For HIV patients 36-months OS was 41 % (95 % CI; 26.7 - 62.7 %) and 59.2 % (95 % CI; 45.8 - 76.6 %) HIV negative HR 1.72 (95 % CI; 0.93 - 1.19 (p = 0.08). Conclusion: this study suggests an OS survival inferior than reported for developed countries with inferior survival rates in HIV patients